A recent study by IBio examined the effects of combining its novel drug IBIO‑610 with the weight‑loss medication semaglutide in obese nonhuman primates. Over eight weeks, researchers observed a significant shift in how body mass was lost, suggesting the combination may preserve muscle while targeting fat more effectively.
The research involved six obese monkeys per group. One group received the standard semaglutide treatment, while another received a single dose of IBIO‑610 alongside twice‑weekly semaglutide injections. The study measured changes in lean body mass and fat content to assess the quality of weight loss.
IBio’s data indicate that the combination therapy reduced lean mass by only 6% of the total weight lost, compared with 22% in the semaglutide‑only group. This suggests that IBIO‑610 helps spare muscle tissue during weight reduction. Additionally, fat loss accounted for 93% of the total weight loss in the combination group, versus 77% in the semaglutide‑only group. The researchers attribute these results to IBIO‑610’s action on metabolic pathways that preferentially mobilize adipose tissue.
IBIO‑610 is designed to modulate specific enzymes involved in lipid metabolism. By enhancing fatty acid oxidation, the drug encourages the body to use stored fat as an energy source. When paired with semaglutide, which slows gastric emptying and reduces appetite, the two agents work synergistically. The primate study showed that the combination not only accelerated weight loss but also maintained a higher proportion of lean mass. This could translate into better long‑term health outcomes for patients who struggle to preserve muscle during dieting.
The study’s methodology included regular body composition scans and blood analyses. Researchers monitored insulin sensitivity, lipid profiles, and inflammatory markers. Results revealed improved insulin sensitivity and reduced triglyceride levels in the combination group, indicating a broader metabolic benefit beyond simple weight loss.
Could a similar strategy help people lose weight without sacrificing muscle? The data from nonhuman primates are promising, but human trials are essential before any clinical recommendations can be made. If the findings translate to humans, IBIO‑610 could become an adjunct to existing GLP‑1 therapies, offering a more balanced approach to weight management. Patients who need to preserve muscle mass—such as athletes or the elderly—might benefit the most.
The next phase will involve phase I safety trials in humans, followed by larger efficacy studies. Regulatory approval will depend on demonstrating that the combination is both safe and superior to current standards of care. If successful, this approach could reshape obesity treatment by focusing on quality of weight loss rather than quantity alone.
Q1: What is the main advantage of adding IBIO‑610 to semaglutide? A1: The combination appears to spare lean muscle while increasing the proportion of fat lost, potentially leading to healthier body composition and better metabolic outcomes.
Q2: How long did the primate study last, and were there any side effects? A2: The study ran for eight weeks with no reported adverse effects in the animals, but human safety data are still pending.
Q3: When might this therapy become available to patients? A3: Human trials are the next step; approval could take several years, depending on trial results and regulatory review.